サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ぶどう膜炎治療の世界市場（2022年～2027年）：動向、シェア、成長、機会、予測
市場調査レポート
商品コード
1091879

ぶどう膜炎治療の世界市場（2022年～2027年）：動向、シェア、成長、機会、予測

Uveitis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
出版日: | 発行: IMARC | ページ情報: 英文 146 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
ぶどう膜炎治療の世界市場（2022年～2027年）：動向、シェア、成長、機会、予測
出版日: 2022年06月13日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のぶどう膜炎治療の市場規模は2021年に15億米ドルとなり、2022年から2027年にかけて5.95％のCAGRで拡大し、2027年に22億米ドルになると予想されています。同市場を牽引する要因には、世界中で光学感染症や慢性的な眼疾患が増加していることなどが挙げられます。

当レポートでは、ぶどう膜炎治療の世界市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、COVID-19の影響、市場機会、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のブドウ膜炎治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 市場内訳：治療タイプ別

  • コルチコステロイド
  • 免疫抑制剤
  • モノクローナル抗体
  • 毛様体筋麻痺薬
  • 抗生物質
  • 抗ウイルス剤
  • 抗真菌剤
  • 鎮痛薬

第7章 市場内訳：疾患タイプ別

  • 前部ブドウ膜炎
  • 後部ブドウ膜炎
  • 中程度ブドウ膜炎
  • 汎静脈炎

第8章 市場内訳：原因別

  • 感染性
  • 非感染性

第9章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東とアフリカ
    • 市場内訳：国別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Alimera Sciences Inc.
    • Bausch & Lomb Incorporated (Bausch Health)
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals Inc.
    • Eyepoint pharmaceuticals Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2021
  • Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2021
  • Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2021
  • Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2021
  • Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2021
  • Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: China: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: India: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: France: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
  • Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
  • Figure 95: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2022-2027
  • Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million US$), 2022-2027
  • Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million US$), 2022-2027
  • Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
  • Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 7: Global: Uveitis Treatment Market Structure
  • Table 8: Global: Uveitis Treatment Market: Key Players
目次
Product Code: SR0622A05_Report

The global uveitis treatment market reached a value of US$ 1.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2027, exhibiting a CAGR of 5.95% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Uveitis treatment refers to various therapeutic procedures for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of eye and sensitivity to light. Some of the commonly used uveitis treatment methods include topical, systemic and local corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, analgesics and antivirals and antifungal medicines. These therapeutics are directed toward reducing inflammation, alleviating pain, preventing further tissue damage and restoring vision loss and can be used to treat conditions, including anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis.

The increasing prevalence of optical infections and chronic eye disorders across the globe represents one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy and autoimmune and inflammatory disorders. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness regarding the available treatment alternatives for managing uveitis has resulted in a significant increase in the demand for corticosteroid treatments among patients and healthcare providers. Additionally, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors. These biological therapeutic agents are effective in the treatment of chronic uveitis and are administered as subcutaneous injections. Other factors, including the implementation of favorable initiatives by the governments to promote public health, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global uveitis treatment market, along with forecasts for at the global, regional and country level from 2022-2027. Our report has categorized the market based on treatment type, disease type, cause and distribution channel.

Breakup by Treatment Type:

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

Breakup by Disease Type:

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

Breakup by Cause:

  • Infectious
  • Non-infectious

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.

Key Questions Answered in This Report:

  • How has the global uveitis treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global uveitis treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the cause?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global uveitis treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Uveitis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Monoclonal Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cycloplegic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Antivirals
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Antifungal
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Analgesics
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Anterior Uveitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Posterior Uveitis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intermediate Uveitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panuveitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cause

  • 8.1 Infectious
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-infectious
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alimera Sciences Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Enzo Biochem Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Eyegate Pharmaceuticals Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Eyepoint pharmaceuticals Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Regeneron Pharmaceuticals Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Santen Pharmaceutical Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis